Experts Identify 8 Stocks for January 7 Trading Gains

STOCK-INVESTMENT-IDEAS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Experts Identify 8 Stocks for January 7 Trading Gains
Overview

Indian markets consolidated on January 6, with benchmarks falling slightly. Analysts are presenting short-term trading ideas, identifying eight 'buy' stocks for potential gains on January 7. Key recommendations include Pidilite Industries, Fortis Healthcare, Sun Pharma, Emcure Pharmaceuticals, and Tata Consumer Products, supported by technical breakouts and favorable chart patterns.

Market Consolidation Continues, Experts Offer Trading Picks

Indian equity benchmarks extended their decline for a second session on January 6, with the market breadth weakening. The National Stock Exchange (NSE) saw 1,801 shares decline against 1,054 advancing. Analysts anticipate this consolidation phase to persist over the upcoming trading sessions. Amidst this cautious sentiment, market experts have put forth several short-term trading recommendations.

Pidilite Industries Poised for Upside

Pidilite Industries, currently trading around ₹1,505, has broken out of a range-bound pattern on decent volumes. Amol Athawale from Kotak Securities suggests a 'Buy' strategy, targeting ₹1,600 with a stop-loss at ₹1,455. A close above ₹1,455 is viewed as a bullish indicator for further momentum.

LIC Shows Accumulation Strength

Life Insurance Corporation of India (LIC) is observed to be in an accumulation zone, trading within a defined range. Recent bullish activity signals strength, with experts projecting a potential breakout. Athawale recommends a 'Buy' for LIC, setting a target of ₹910 and a stop-loss of ₹820, with ₹820 acting as a crucial trend-decider level.

Sun Pharma Eyes Further Gains

Sun Pharmaceutical Industries has experienced a sharp upside breakout this week, moving past key moving averages. Nagaraj Shetti of HDFC Securities views this as a precursor to further upside momentum. With expanding volumes and positive RSI signals, Shetti advises a 'Buy', targeting ₹1,905 and setting a stop-loss at ₹1,685.

Emcure Pharmaceuticals Sees Bullish Sentiment Shift

Emcure Pharmaceuticals has decisively surpassed its consolidation resistance around ₹1,470. The stock's weekly pattern suggests a shift towards bullishness, with a consistent higher tops and higher bottoms formation intact. Expanding volumes and positive RSI indicators support a 'Buy' recommendation from Shetti, who targets ₹1,655 and sets a stop-loss at ₹1,458.

NAVA Breaks Out of Range

NAVA has achieved a decisive upside breakout at the ₹440 level after weeks of range-bound trading. Shetti highlights that the positive sequence of higher tops and bottoms remains robust. With strong volume support and favorable RSI readings, NAVA is also a 'Buy' candidate, aiming for ₹660 with a stop-loss at ₹580.

Fortis Healthcare Forms Rounding Bottom

Fortis Healthcare has demonstrated strength by closing above its neckline at ₹941, confirming a rounding bottom pattern. Ashish Kyal from Waves Strategy Advisors notes the stock's resilience and its close above the 50 EMA. Kyal suggests a 'Buy' strategy for dips, targeting ₹985 and ₹1,030, with a stop-loss at ₹895.

Aurobindo Pharma Reverses Trend

Aurobindo Pharma is on the verge of breaking out from an inverse head-and-shoulders pattern after finding support near its 60-day EMA. The stock shows a bullish MACD crossover and is nearing a decisive breakout above ₹1,242. Kyal recommends a 'Buy', targeting ₹1,320, and places a stop-loss at ₹1,190.

Tata Consumer Products Respects Trendline

Tata Consumer Products continues to respect its upward-sloping trendline and has decisively broken above its prior swing high. The stock's ADX indicates strengthening bullish momentum. Kyal advises a 'Buy on dips' strategy, with targets set at ₹1,250 and ₹1,280, and a strict stop-loss at ₹1,165.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.